Vol 19, No 1 (2016)

Articles
WEEK OF OSTEOPOROSIS AND OTHER METABOLIC BONE DISEASES AT ENDOCRINOLOGY RESEARCH CENTER RUSSIAN MINISTRY OF HEALTH
Belaya Z.E.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):3-3
views
DIAGNOSIS OF OSTEOPOROSIS
Kanis J.A.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):4-5
views
FROM REPLICATIVE SENESCENCE TO MICRORNA BASED DIAGNOSTICS OF AGE-ASSOCIATED DISEASES
Hackl M., Weilner S., Heilmayer U., Skalicky S., Schröder F., Schraml E., Vierlinger K., Link T., Grillari J.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):5-7
views
MICRORNAS: FROM BIOLOGY TO CLINICAL IMPLEMENTATION
Nonn L.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):7-8
views
NONINVASIVE ASSESSMENT OF BONE QUALITY IN CLINICAL ROUTINE
Hans D.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):8-11
views
BONE AND METABOLIC CONTROL
Bonnet N.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):12-13
views
PRINCIPLES OF GENETIC DIAGNOSIS OF SKELETAL DYSPLASIAS
Asanov A.Y.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):13-13
views
WNT-SIGNALING PATHWAY IN THE BONE TISSUE STUDIES
Belaya Z.E.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):13-14
views
CLINICAL EXOME SEQUENCING TO DETECT GENETICALLY DETERMINED DISEASES OF THE SKELETON
Kanivets I.V., Konovalov F.A., Korostelev S.A., Belova N.A., Katasonov F.S., Piankov D.V., Khmelkova D.N.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):15-15
views
EPIGENETIC REGULATION IN BONE TISSUE
Nikitin A.G., Belaya Z.E., Brovkina O.I., Grebennikova T.A., Khodyrev D.S., Khandaeva P.M., Koshkin F.A., Melnichenko G.A.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):15-16
views
DIAGNOSTIC POSSIBILITIES OF THE VARIOUS METHODS FOR THE IDENTIFICATION OF HIGH FRACTURE RISK POPULATIONS (FRAX®, DENSITOMETRY)
Nikitinskaya O.A., Toroptsova N.V., Demin N.V.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):16-17
views
PAGET'S DISEASE OF BONE: CLINICAL PRESENTATION OF ENDO RECOMMENDATIONS AND UPDATING THEM IN RUSSIA
Pigarova E.A.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):17-18
views
MUSCULOSKELETAL COMPLICATIONS OF HYPERCORTISOLISM AND ACROMEGALY
Rozhinskaya L.Y.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):18-19
views
SARCOPENIA AND FALLS IN THE ELDERLY: POSSIBILITIES FOR PREVENTION
Skripnikova I.A.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):19-20
views
EVIDENCE-BASED MEDICINE. THE PRINCIPLES OF RESEARCH PLANNING. FROM DESIGN TO STATISTICAL ANALYSIS OF THE DATA
Solodovnikov A.G.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):20-20
views
RADIOGRAPHIC METHODS OF DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF METABOLIC DISEASES OF THE SKELETON
Torbaeva N.V.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):20-21
views
HEREDITARY DISORDERS OF CALCIUM-PHOSPHORUS METABOLISM: DIAGNOSIS AND TREATMENT
Tiulpakov A.N.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):21
views
DXA IN THE DIAGNOSIS OF OSTEOPOROSIS
Chernova T.O.
Abstract
Osteoporosis and Bone Diseases. 2016;19(1):21-21
views
EFFECT OF A 5-YEAR ALFACALCIDOL TREATMENT IN COMBINATION WITH CALCIUM CARBONATE ON BONE MINERAL DENSITY IN THE PRIMARY FORMS OF SYSTEMIC OSTEOPOROSIS IN MEN
Rodionova S.S., Khakimov U.R.
Abstract
The article presents the results of 5-year treatment with a combination of alfacalcidol and calcium carbonate in 47 men with primary forms of systemic osteoporosis. The obtained results show the effectiveness of this treatment in patients with low and normal turnover forms of osteoporosis. Significant increase of BMD at L1-L4 was observed after the first year of treatment, at the Neck region - after 3-rd year of treatment. Comparison of the magnitude of the annual increase of BMD has shown that the effectiveness of the treatment increases with its duration. The possibility of hypercalcemia was excluded by monitoring of calcium levels in blood and urine at intervals of 3-6 months throughout the treatment period.
Osteoporosis and Bone Diseases. 2016;19(1):22-27
views
THE ROLE OF MYOKINES INTERSTITIAL INTERACTION AND REGULATION OF METABOLISM: A REVIEW OF LITERATURE
Tsoriev T.T., White Z.E., Rozhinskaya L.Y.
Abstract
Myokines are hormone-like acting molecules produced in skeletal muscles during and immediately after exercise. They affect both paracrine (inside the muscles themselves) and endocrine manner (in adipose tissue, liver, endothelium, skin, mucosa etc.) implementing different effects on target tissues, mainly through regulation of metabolic processes (such as glucose and lipid metabolism, growth and division of neurons and endothelial cells and others). The examination of myokines is of great interest for researchers of different medicine departments, particularly for endocrinologists, because of myokines’ involvement in pathogenesis of abdominal and visceral obesity, diabetes mellitus type 2 and cardiovascular diseases that are all the components of metabolic syndrome. The most important issue for clinicians is a possibility of future therapeutic implication of the myokine’s signal pathways in treatment of widespread metabolic disorders.
Osteoporosis and Bone Diseases. 2016;19(1):28-34
views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies